GSK 6-K
GSK plc (GSK)
6-K
2025-10-15
For: 2025-10-15
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Emma<br>Walmsley | ||
| b) | Position/status | Chief<br>Executive Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 1,355 | |||
| £16.4000 | 1,531 | |||
| £16.4000 | 1,038 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 3,924<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Julie<br>Brown | ||
| b) | Position/status | Chief<br>Financial Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 680 | |||
| £16.4000 | 584 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,264<br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Diana<br>Conrad | ||
| b) | Position/status | Chief<br>People Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 152 | |||
| £16.4000 | 386 | |||
| £16.4000 | 246 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 784<br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | James<br>Ford | ||
| b) | Position/status | SVP<br>and Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 239 | |||
| £16.4000 | 237 | |||
| £16.4000 | 391 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 867<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Sally<br>Jackson | ||
| b) | Position/status | SVP,<br>Global Communications and CEO Office | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 242 | |||
| £16.4000 | 149 | |||
| £16.4000 | 133 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 524<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Luke<br>Miels | ||
| b) | Position/status | Chief<br>Commercial Officer | ||
| c) | Initial<br>notification/<br><br>amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 365 | |||
| £16.4000 | 578 | |||
| £16.4000 | 727 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,670<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Shobie<br>Ramakrishnan | ||
| b) | Position/status | Chief<br>Digital and Technology Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in ADSs following the re-investment of<br>dividends paid to shareholders on 9 October 2025 on ADSs held in<br>the Company's Deferred Annual Bonus Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $43.4400 | 119 | |||
| $43.4400 | 112 | |||
| $43.4400 | 186 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 417<br><br><br><br>43.4400 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | David<br>Redfern | ||
| b) | Position/status | President,<br>Corporate Development | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 463 | |||
| £16.4000 | 334 | |||
| £16.4000 | 211 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,008<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Regis<br>Simard | ||
| b) | Position/status | President,<br>Global Supply Chain | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 309 | |||
| £16.4000 | 557 | |||
| £16.4000 | 268 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,134<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Philip<br>Thomson | ||
| b) | Position/status | President,<br>Global Affairs | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 188 | |||
| £16.4000 | 311 | |||
| £16.4000 | 175 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 674<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Deborah<br>Waterhouse | ||
| b) | Position/status | CEO,<br>ViiV Healthcare and President, Global Health, GSK | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 427 | |||
| £16.4000 | 482 | |||
| £16.4000 | 290 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volum<br><br>Price | 1,199<br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Tony<br>Wood | ||
| b) | Position/status | Chief<br>Scientific Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 October 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.4000 | 594 | |||
| £16.4000 | 202 | |||
| £16.4000 | 271 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,067<br><br><br><br>16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Emma<br>Walmsley | |||
| b) | Position/status | Chief<br>Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN:<br>GB00BN7SWP63 | |||
| b) | Nature of<br>the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 9 October 2025 on Ordinary Shares held in the<br>Company's Performance Share Plan subject to a 2-year holding<br>period | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £16.4000 | 4,590.351 | ||||
| £16.4000 | 4,196.389 | ||||
| d) | Aggregated information<br><br>Aggregated volume<br><br>Price | N/A<br>(single transaction)<br><br>8,786.741<br><br>£16.4000 | |||
| e) | Date<br>of the transaction | 2025-10-10 | |||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David<br>Redfern | |||
| b) | Position/status | President<br>Corporate Development | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN:<br>GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 9 October 2025 on Ordinary Shares held within an<br>ISA | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £16.3499 | 20 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2025-10-10 | |||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria<br>Whyte | |||
| b) | Position/status | Company<br>Secretary | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br>ISIN:<br>GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 9 October 2025 on Ordinary Shares held within an<br>ISA | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £16.3499 | 17 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2025-10-10 | |||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: October<br>15, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |